Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vigil Neuroscience Inc (VIGL – Research Report), Medicine Man Technologies (SHWZ – Research Report) and BioLife Solutions (BLFS – Research Report).
Vigil Neuroscience Inc (VIGL)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc, with a price target of $24.00. The company’s shares closed last Thursday at $6.67.
According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Vigil Neuroscience Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.00, implying a 194.1% upside from current levels. In a report issued on November 13, Mizuho Securities also maintained a Buy rating on the stock with a $13.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Medicine Man Technologies (SHWZ)
In a report released today, Mike Hickey from Benchmark Co. maintained a Buy rating on Medicine Man Technologies, with a price target of $3.00. The company’s shares closed last Thursday at $0.60, close to its 52-week low of $0.51.
According to TipRanks.com, Hickey is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Medicine Man Technologies is a Moderate Buy with an average price target of $3.00.
BioLife Solutions (BLFS)
In a report released today, Robert Wasserman from Benchmark Co. maintained a Hold rating on BioLife Solutions. The company’s shares closed last Thursday at $11.96.
According to TipRanks.com, Wasserman is ranked 0 out of 5 stars with an average return of
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $22.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIGL:
- Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
- Vigil Neuroscience reports Q3 EPS (53c), consensus (57c)
- Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
- Arm initiated, SQM downgraded: Wall Street’s top analyst calls
- Vigil Neuroscience initiated with an Outperform at JMP Securities
